Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 15/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.38 |
| ▸ | STAT6 | P42226 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.36 |
| ▸ | GUCY1A1 | Q02108 | 1/20 | 0.35 |
| ▸ | GUCY1B1 | Q02153 | 1/20 | 0.35 |
| ▸ | CD38 | P28907 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19010300 | 0.92 | GUCY1A1 (0.34) | SYKAURKAPDPK1RPS6KB1STAT6 | |
| SCHEMBL17021270 | 0.87 | SYK (0.42) | SYKAURKAPDPK1RPS6KB1STAT6 | |
| SCHEMBL17021435 | 0.81 | AURKA (0.39) | SYKAURKAPDPK1RPS6KB1STAT6 | |
| SCHEMBL19010283 | 0.80 | SYK (0.38) | SYKAURKAPDPK1RPS6KB1STAT6 | |
| SCHEMBL19021939 | 0.79 | MAPK10 (0.39) | SYKSTAT6 | |
| SCHEMBL17021322 | 0.78 | JAK3 (0.53) | — | |
| SCHEMBL17021396 | 0.78 | JAK3 (0.51) | SYKAURKAPDPK1RPS6KB1STAT6 | |
| SCHEMBL17021276 | 0.78 | STAT6 (0.62) | STAT6 | |
| SCHEMBL17021286 | 0.78 | TYK2 (0.43) | AURKAPDPK1RPS6KB1STAT6 | |
| SCHEMBL17021367 | 0.76 | RPS6KB1 (0.43) | SYKAURKARPS6KB1STAT6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9834548-B2 | Pyridazine compounds as JAK inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-9834548-B2 | Pyridazine compounds as JAK inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20170174673-A1 | PYRIDAZINE COMPOUNDS AS JAK INHIBITORS | ALEXION PHARMACEUTICALS, INC. | 2017-06-22 | — | — | US | disclosed |
| US-20170174673-A1 | PYRIDAZINE COMPOUNDS AS JAK INHIBITORS | ALEXION PHARMACEUTICALS, INC. | 2017-06-22 | — | — | US | disclosed |
| WO-2015123453-A1 | PYRIDAZINE COMPOUNDS AS JAK INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2015-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174673-A1 | PYRIDAZINE COMPOUNDS AS JAK INHIBITORS | JAK1, JAK2, JAK3 | SYK 248/4885AURKA 175/4885PDPK1 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.